Does metformin modify ovarian responsiveness during exogenous FSH ovulation induction in normogonadotrophic anovulation? A placebo-controlled double-blind assessment

European Journal of Endocrinology

Volumn 152, Issue 4, 2005, Pages 611-617

  van Santbrink, Evert J P ^a   Hohmann, Femke P ^a   Eijkemans, Marinus J C ^a   Laven, Joop S E ^a   Fauser, Bart C J M ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; CHORIONIC GONADOTROPIN; ESTRADIOL; FOLLITROPIN; INSULIN; LUTEINIZING HORMONE; METFORMIN; PLACEBO; RECOMBINANT FOLLITROPIN; TESTOSTERONE;

ADULT; ANDROSTENEDIONE BLOOD LEVEL; ANOVULATION; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG POTENTIATION; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; GASTROINTESTINAL DISEASE; HORMONE RESPONSE; HUMAN; INSULIN RESISTANCE; LOW DRUG DOSE; LUTEINIZING HORMONE BLOOD LEVEL; OVARY CYCLE; OVULATION INDUCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; WITHDRAWAL BLEEDING;

ADOLESCENT; ADULT; ANOVULATION; CHORIONIC GONADOTROPIN; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; METFORMIN; OVULATION INDUCTION; PLACEBOS;

EID: 17744383191     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.01866     Document Type: Article

References (36)

1. Aboulghar MA & Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Human Reproduction Update 2003 9 275-289.
2. Fauser BC & Macklon NS. Medical approaches to ovarian stimulation for infertility. In Yen and Jaffes Reproductive Endocrinology, edn 5, pp 965-1012. Eds JF Strauss & RL Barbieri. Philadelphia: Elsevier Saunders Inc., 2004.
3. Brown JB. Pituitary control of ovarian function - concepts derived from gonadotrophin therapy. Australian and New Zealand Journal of Obstetrics and Gynaecology 1978 18 46-54.
4. Fauser BC & van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocrine Reviews 1997 18 71-106.
5. Imani B, Eijkemans MJ, Faessen G, Bouchard P, Giudice LC & Fauser BC. Prediction of the individual FSH-threshold for gonadotrophin induction of ovulation in anovulatory infertility: an approach to minimize multiple gestation, ovarian hyperstimulation, and treatment expense. Fertility and Sterility 2002 77 83-90.
6. Mulders AG, Eijkemans MJ, Imani B & Fauser BCJM. Prediction of chances for success or complications in gonadotrophin ovulation induction in normogonadotrophic anovulatory infertility. Reproductive BioMedicine Online 2003 7 48-56.
7. van Santbrink EJP & Fauser BCJM. Urinary follicle-stimulating hormone for normogonadotropic clomiphene-resistant anovulatory infertility: prospective, randomized comparison between low-dose step-up and step-down dose regimens. Journal of Clinical Endocrinology and Metabolism 1997 82 3597-3602.
8. Fisher SA, Reid RL, van Vught DA & Casper RF. A randomized double blind comparison of the effects of CC and the aromatase inhitor Letrozole on the ovulatory function in normal women. Fertility and Sterility 2002 78 280-285.
9. Nestler JE & Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. New England Journal of Medicine 1996 335 617-623.
10. PCOS consensus. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 2004 19 41-47.
11. PCOS consensus, The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Fertility and Sterility 2004 81 19-25.
12. Gilling-Smith C, Willis DS, Beard RW & Franks S. Hypersecretion of AD by isolated thecal cells from polycystic ovaries. Journal of Clinical Endocrinology and Metabolism 1994 79 1158-1165.
13. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanisms and implications for pathogenesis. Endocrine Reviews 1997 18 774-800.
14. Erickson GF, Magoffin DA, Cragun JR & Chang RJ. The effects of insulin and insulin-like growth factor-I and -II on estradiol production by granulosa cells of polycystic ovaries. Journal of Clinical Endocrinology and Metabolism 1990 70 894-902.
15. Coffler MS, Patel K, Dahan MH, Yoo RY, Malcom PJ & Chang RJ. Enhanced granulosa cell responsiveness to FSH during insulin infusion in women with PCOS treated with Pioglitazone. Journal of Clinical Endocrinology and Metabolism 2003 88 5624-5631.
16. Franks S, Gilling-Smith C, Watson R & Willis D. Insulin action in the normal and polycystic ovary. Endocrinology and Metabolism Clinics of North America 1999 28 361-378.
17. la Marca A, Egbe TO, Morgante G, Palia T, Ciani A & De Leo V. Metformin treatment reduces ovarian cytochrome p-450c17α response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome. Human Reproduction 2000 15 21-23.
18. Mu YM, Yanase T, Nishi Y, Waseda N, Oda T, Tanaka A, Takayanagi R & Nawata H. Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells. Biochemical and Biophysical Research Communications 2000 19 710-713.
19. la Marca A, Morgante G, Palumbo M, Ciani A, Petraglia F & De Leo V. Insulin-lowering treatment reduces aromatase activity in response to follicle-stimulating hormone in women with polycystic ovary syndrome. Fertility and Sterility 2002 78 1234-1239.
20. Nestler JE & Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. Journal of Clinical Endocrinology and Metabolism 1997 82 4075-4079.
21. Lord JM, Flight IHK & Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. British Medical Journal 2003 327 951-953.
22. Velazquez E, Acosta A & Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstetrics and Gynecology 1997 90 392-395.
23. Diamanti-Kandarakis E, Kouli C, Tsianateli T & Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome (see comments). European Journal of Endocrinology 1998 138 269-274.
24. Morin-Papunen LC, Koivunen RM, Ruokonen A & Martikainen HK. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertility and Sterility 1998 69 691-696.
25. de Leo V, la Marca A, Ditto A, Morgante G & Cianci A. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertility and Sterility 1999 72 282-285.
26. Yarali H, Yildiz BO, Demirol A, Zeyneloglu HB, Yigit N, Bukulmez O & Koray Z. Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction 2002 17 289-294.
27. Nestler JE, Jakubowicz DJ, Evans WS & Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine 1998 338 1876-1880.
28. Homburg R, Orvieto R, Bar-Hava I & Ben-Rafael Z. Serum levels of insulin-like growth factor-1, IGF binding protein-1 and insulin and the response to human menopausal gonadotrophins in women with polycystic ovary syndrome. Human Reproduction 1996 11 716-719.
29. Legro RS, Finegood D & Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 1998 83 2694-2698.
30. White DM, Polson DW & Kiddy D. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analyis of 109 pregnancies in 225 women. Journal of Clinical Endocrinology and Metabolism 1996 81 3821-3824.
31. Imani B, Eijkemans MJ, te Velde ER, Habbema JD & Pauser BC. Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Journal of Clinical Endocrinology and Metabolism 1999 84 1617-1622.
32. Polson DW, Kiddy DS, Mason HD & Franks S. Induction of ovulation with clomiphene citrate in women with polycystic ovary syndrome: the difference between responders and nonresponders. Fertility and Sterility 1989 51 30-34.
33. Imani B, Eijkemans MJ, te Velde ER, Habbema JD & Fauser BC. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Journal of Clinical Endocrinology and Metabolism 1998 83 2361-2365.
34. Imani B, Eijkemans MJ, de Jong F, Payne NN, Bouchard P, Giudice LC & Fauser BC. Free androgen index and leptin are the most prominent endocrine predictors of ovarian response during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Journal of Clinical Endocrinology and Metabolism 2000 85 676-682.
35. Galtier-Dereure F, Pujol P, Dewailly D & Bringer J. Choice of stimulation in polycystic ovarian syndrome: the influence of obesity. Human Reproduction 1997 12 (Suppl 1) 88-96.
36. Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortolani F & Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertility and Sterility 2004 8 114-119.